Prolonged duration of action of active substances

The term 'Prolonged duration of action of active substances' refers to a pharmacokinetic characteristic or a therapeutic objective in pharmacology, rather than a specific biological target, receptor, or enzyme. It describes the extension of time during which a medicinal compound remains at therapeutic concentrations within the body, typically aimed at reducing dosing frequency and improving patient compliance. This effect is achieved through various drug delivery technologies, such as sustained-release matrices and depot formulations, or via molecular engineering strategies like pegylation or fusion to the neonatal Fc receptor (FcRn) binding domain of antibodies. Because it represents a physiological outcome or a property of a drug product, it does not possess a unique molecular structure, biological family, or direct role in disease pathology. Consequently, it is classified as an incorrect target designation for drug-receptor interaction studies.

Other names

Extended releaseLong-acting effectSustained releaseDelayed-actionPharmacokinetic prolongation

This is a pharmacokinetic property or therapeutic goal rather than a molecular mechanism. It is achieved via formulation techniques (e.g., microencapsulation, depot injections) or chemical modifications (e.g., pegylation, fatty acid conjugation) that slow the absorption, distribution, metabolism, or excretion (ADME) of a drug.